WASHINGTON TRUST Co Buys 2,671 Shares of Eli Lilly and Company (NYSE:LLY)

WASHINGTON TRUST Co lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 16.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,892 shares of the company’s stock after acquiring an additional 2,671 shares during the quarter. WASHINGTON TRUST Co’s holdings in Eli Lilly and Company were worth $11,013,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares during the period. State Street Corp lifted its holdings in Eli Lilly and Company by 1.9% in the 2nd quarter. State Street Corp now owns 33,878,417 shares of the company’s stock worth $15,888,300,000 after purchasing an additional 642,274 shares in the last quarter. Morgan Stanley lifted its holdings in Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after purchasing an additional 83,915 shares in the last quarter. Northern Trust Corp lifted its holdings in Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after purchasing an additional 355,317 shares in the last quarter. Finally, Norges Bank purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $3,416,206,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.2 %

Eli Lilly and Company stock traded up $1.50 during mid-day trading on Wednesday, hitting $776.40. The company’s stock had a trading volume of 1,127,984 shares, compared to its average volume of 3,216,364. Eli Lilly and Company has a one year low of $334.58 and a one year high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The company has a 50 day moving average of $725.15 and a 200-day moving average of $634.68. The stock has a market cap of $737.70 billion, a PE ratio of 133.55, a P/E/G ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the company earned $2.09 EPS. The business’s revenue was up 28.1% compared to the same quarter last year. On average, research analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Morgan Stanley upped their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, February 20th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $689.52.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 195,055 shares of company stock valued at $125,254,657. 0.13% of the stock is currently owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.